GW Henssler & Associates Ltd. Makes New $289,000 Investment in Pfizer Inc. (NYSE:PFE)

GW Henssler & Associates Ltd. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,001 shares of the biopharmaceutical company’s stock, valued at approximately $289,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Pfizer by 16.0% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 41,275 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 5,682 shares during the period. Exchange Capital Management Inc. grew its holdings in shares of Pfizer by 1.4% in the 1st quarter. Exchange Capital Management Inc. now owns 35,048 shares of the biopharmaceutical company’s stock valued at $973,000 after buying an additional 500 shares during the period. Naviter Wealth LLC grew its holdings in shares of Pfizer by 80.9% in the 1st quarter. Naviter Wealth LLC now owns 38,987 shares of the biopharmaceutical company’s stock valued at $1,082,000 after buying an additional 17,430 shares during the period. Plimoth Trust Co. LLC lifted its position in Pfizer by 2.2% in the 1st quarter. Plimoth Trust Co. LLC now owns 64,723 shares of the biopharmaceutical company’s stock valued at $1,796,000 after acquiring an additional 1,406 shares in the last quarter. Finally, Tradewinds Capital Management LLC lifted its position in Pfizer by 27.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 2,330 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Citigroup initiated coverage on shares of Pfizer in a research report on Friday. They issued a “neutral” rating and a $30.00 price objective on the stock. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.60 during trading on Tuesday, hitting $28.26. 49,506,754 shares of the stock were exchanged, compared to its average volume of 36,915,188. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The stock has a market capitalization of $160.14 billion, a price-to-earnings ratio of -61.22, a price-to-earnings-growth ratio of 0.99 and a beta of 0.67. The company has a fifty day moving average price of $29.08 and a 200-day moving average price of $28.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the business earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. Pfizer’s dividend payout ratio (DPR) is currently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.